Lung cancer remains one of the most common leading causes of cancer related deaths globally. Although there has been significant development in the treatment and therapy for lung cancer patients, the overall survival rate and prognosis remain poor. Approximately, over 2 million people are diagnosed with lung cancer on an annual basis and a 5-year survival rate varies between 4-17%, depending on the stage of the disease and regional differences.
Immunotherapy is a developing field in oncology with an aim to advance potential therapies and treatments for various cancers. The basis of immunotherapy is to evoke an anti-tumor immune response by blocking an immune checkpoint such as programmed death-1/programmed death ligand-1 (PD-1/PD-L1) and cytotoxic T-cell lymphocyte antigen-4 which would potentially suppress and control the tumor. Unfortunately, there has been limited success with immunotherapy as treatment with approximately less than 30% of non-small cell lung cancer (NSCLC) patients responding to immunotherapy. Therefore, further research is required with the potential search of identifying biomarkers to determine NSCLC patients who are most likely to respond to immunotherapy.
Studies have suggested several biomarkers including PD-1/PD-L1 expression on tumor cells, the infiltration of T-cells within the tumor microenvironment and tumor mutations are associated with the therapeutic response of NSCLC to immunotherapy. However, these are challenging to study further due to the requirement of tumor biopsy, particularly in patients who are at an advanced stage of the disease. There are also lifestyle factors which have been considered to impact the response of immunotherapy in lung cancer patients such as smoking, which is known to impact the immune microenvironment and tumor mutations in lung cancer which could be potentially associated with the therapeutic efficacy of immunotherapy. However, further studies are required to establish a relationship between smoking and whether it has a significant impact on the response to immunotherapy.
Immunotherapy remains a core area of interest in the developing field of oncology. The aim of this Research Topic is to generate a discussion on how immunotherapy influences and impacts the prognosis and overall survival rate for lung cancer patients. We welcome Original Research Articles, Review Articles, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Lung cancer remains one of the most common leading causes of cancer related deaths globally. Although there has been significant development in the treatment and therapy for lung cancer patients, the overall survival rate and prognosis remain poor. Approximately, over 2 million people are diagnosed with lung cancer on an annual basis and a 5-year survival rate varies between 4-17%, depending on the stage of the disease and regional differences.
Immunotherapy is a developing field in oncology with an aim to advance potential therapies and treatments for various cancers. The basis of immunotherapy is to evoke an anti-tumor immune response by blocking an immune checkpoint such as programmed death-1/programmed death ligand-1 (PD-1/PD-L1) and cytotoxic T-cell lymphocyte antigen-4 which would potentially suppress and control the tumor. Unfortunately, there has been limited success with immunotherapy as treatment with approximately less than 30% of non-small cell lung cancer (NSCLC) patients responding to immunotherapy. Therefore, further research is required with the potential search of identifying biomarkers to determine NSCLC patients who are most likely to respond to immunotherapy.
Studies have suggested several biomarkers including PD-1/PD-L1 expression on tumor cells, the infiltration of T-cells within the tumor microenvironment and tumor mutations are associated with the therapeutic response of NSCLC to immunotherapy. However, these are challenging to study further due to the requirement of tumor biopsy, particularly in patients who are at an advanced stage of the disease. There are also lifestyle factors which have been considered to impact the response of immunotherapy in lung cancer patients such as smoking, which is known to impact the immune microenvironment and tumor mutations in lung cancer which could be potentially associated with the therapeutic efficacy of immunotherapy. However, further studies are required to establish a relationship between smoking and whether it has a significant impact on the response to immunotherapy.
Immunotherapy remains a core area of interest in the developing field of oncology. The aim of this Research Topic is to generate a discussion on how immunotherapy influences and impacts the prognosis and overall survival rate for lung cancer patients. We welcome Original Research Articles, Review Articles, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
